Literature DB >> 10616794

Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis.

K E Saatman1, C Zhang, R T Bartus, T K McIntosh.   

Abstract

Administration of the selective calpain inhibitor AK295 has been shown to attenuate motor and cognitive dysfunction after brain trauma in rats. To explore mechanisms underlying the behavioral efficacy of posttraumatic calpain inhibition, we investigated histologic consequences of AK295 administration. Anesthetized Sprague-Dawley rats received lateral fluid percussion brain injury of moderate severity (2.2 to 2.4 atm) or served as uninjured controls. At 15 minutes after injury, animals were randomly assigned to receive a 48-hour infusion of either 2 mmol/L AK295 (120 to 140 mg/kg) or saline via the carotid artery. At 48 hours and 1 week after injury, spectrin fragments generated specifically by calpain were detected by Western blotting and immunohistochemistry, respectively, in saline-treated, brain-injured animals. Interestingly, equivalent spectrin breakdown was observed in AK295-treated animals when cortical and hippocampal regions were evaluated. Similarly, administration of the calpain inhibitor did not attenuate cortical lesion size or the numbers of apoptotic cells in the cortex, subcortical white matter, or hippocampus, as verified by terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick-end labeling and morphology, at 48 hours after injury. These data suggest that an overt reduction in spectrin proteolysis, cortical lesion, or apoptotic cell death at 48 hours or 1 week is not required for behavioral improvements associated with calpain inhibition by AK295 after experimental brain injury in rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10616794     DOI: 10.1097/00004647-200001000-00010

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  13 in total

Review 1.  Axonal pathology in traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Exp Neurol       Date:  2012-01-20       Impact factor: 5.330

2.  A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model.

Authors:  Stephanie N Thompson; Kimberly M Carrico; Ayman G Mustafa; Mona Bains; Edward D Hall
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

3.  Sustained calpain inhibition improves locomotor function and tissue sparing following contusive spinal cord injury.

Authors:  Chen-Guang Yu; James W Geddes
Journal:  Neurochem Res       Date:  2007-05-03       Impact factor: 3.996

4.  Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury.

Authors:  Chen-Guang Yu; Aashish Joshi; James W Geddes
Journal:  J Neurotrauma       Date:  2008-07       Impact factor: 5.269

5.  Pharmacological inhibition of lipid peroxidation attenuates calpain-mediated cytoskeletal degradation after traumatic brain injury.

Authors:  Ayman G Mustafa; Juan A Wang; Kimberly M Carrico; Edward D Hall
Journal:  J Neurochem       Date:  2011-03-22       Impact factor: 5.372

6.  Targeted gene inactivation of calpain-1 suppresses cortical degeneration due to traumatic brain injury and neuronal apoptosis induced by oxidative stress.

Authors:  Kaori H Yamada; Dorothy A Kozlowski; Stacey E Seidl; Steven Lance; Adam J Wieschhaus; Premanand Sundivakkam; Chinnaswamy Tiruppathi; Imran Chishti; Ira M Herman; Shafi M Kuchay; Athar H Chishti
Journal:  J Biol Chem       Date:  2012-02-24       Impact factor: 5.157

7.  Calpains and delayed calcium deregulation in excitotoxicity.

Authors:  Inês M Araújo; Bruno P Carreira; Caetana M Carvalho; Arsélio P Carvalho
Journal:  Neurochem Res       Date:  2010-11-26       Impact factor: 3.996

8.  Therapy development for diffuse axonal injury.

Authors:  Douglas H Smith; Ramona Hicks; John T Povlishock
Journal:  J Neurotrauma       Date:  2013-02-14       Impact factor: 5.269

9.  Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse.

Authors:  Kathleen M Schoch; Catherine R von Reyn; Jifeng Bian; Glenn C Telling; David F Meaney; Kathryn E Saatman
Journal:  J Neurochem       Date:  2013-02-03       Impact factor: 5.372

10.  Calpastatin overexpression limits calpain-mediated proteolysis and behavioral deficits following traumatic brain injury.

Authors:  Kathleen M Schoch; Heather N Evans; Jennifer M Brelsfoard; Sindhu K Madathil; Jiro Takano; Takaomi C Saido; Kathryn E Saatman
Journal:  Exp Neurol       Date:  2012-05-01       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.